Natera, Inc. (NASDAQ:NTRA) Insider Sells $398,670.00 in Stock

Key Points

• Insider Solomon Moshkevich sold 3,000 shares of Natera, Inc. stock for $398,670.00, reducing his ownership by 2.38% to 123,059 shares valued at approximately $16.35 million.
• Natera's shares rose by $3.55 to reach $140.12, with a market capitalization of $19.13 billion and a one-year low of $97.24.
• The company reported a 36.5% revenue increase year-over-year, totaling $501.83 million for the quarter, along with a negative earnings per share of ($0.50) which beat analyst estimates.

Natera, Inc. (NASDAQ:NTRA - Get Free Report) insider Solomon Moshkevich sold 3,000 shares of the firm's stock in a transaction on Friday, August 1st. The stock was sold at an average price of $132.89, for a total value of $398,670.00. Following the completion of the sale, the insider directly owned 123,059 shares of the company's stock, valued at $16,353,310.51. The trade was a 2.38% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Solomon Moshkevich also recently made the following trade(s):

• On Monday, July 28th, Solomon Moshkevich sold 2,206 shares of Natera stock. The stock was sold at an average price of $139.81, for a total value of $308,420.86.
• On Monday, July 21st, Solomon Moshkevich sold 291 shares of Natera stock. The stock was sold at an average price of $139.29, for a total value of $40,533.39.
• On Tuesday, May 27th, Solomon Moshkevich sold 1,649 shares of Natera stock. The stock was sold at an average price of $156.85, for a total value of $258,645.65.
• On Tuesday, July 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $166.77, for a total value of $500,310.00.
• On Monday, June 2nd, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $157.07, for a total value of $471,210.00.

Natera Stock Performance

Shares of Natera stock traded up $3.55 on Tuesday, hitting $140.12. The company's stock had a trading volume of 2,254,383 shares, compared to its average volume of 1,290,655. Natera, Inc. has a 1 year low of $97.24 and a 1 year high of $183.00. The firm has a fifty day moving average price of $156.49 and a 200-day moving average price of $155.43. The company has a market capitalization of $19.13 billion, a price-to-earnings ratio of -95.32 and a beta of 1.76.

Natera (NASDAQ:NTRA - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The medical research company reported ($0.50) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.59) by $0.09. Natera had a negative return on equity of 18.29% and a negative net margin of 10.36%. The company had revenue of $501.83 million for the quarter, compared to analysts' expectations of $446.68 million. During the same period in the previous year, the firm posted ($0.56) EPS. Natera's revenue was up 36.5% compared to the same quarter last year. As a group, analysts forecast that Natera, Inc. will post -1.49 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have commented on NTRA. Evercore ISI raised Natera to a "strong-buy" rating and set a $170.00 price target for the company in a research report on Monday, July 28th. Barclays lifted their price objective on Natera from $160.00 to $190.00 and gave the company an "overweight" rating in a research note on Friday, May 9th. Wall Street Zen lowered Natera from a "hold" rating to a "sell" rating in a research note on Saturday, May 17th. UBS Group lifted their price objective on Natera from $211.00 to $218.00 and gave the company a "buy" rating in a research note on Friday, May 9th. Finally, Piper Sandler lifted their price objective on Natera from $205.00 to $210.00 and gave the company an "overweight" rating in a research note on Thursday, May 15th. One research analyst has rated the stock with a sell rating, fifteen have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $183.76.

Institutional Investors Weigh In On Natera

Several institutional investors have recently bought and sold shares of the company. Machina Capital S.A.S. acquired a new stake in Natera in the 2nd quarter worth about $362,000. Mission Wealth Management LP acquired a new stake in Natera in the 2nd quarter worth about $228,000. Zweig DiMenna Associates LLC boosted its holdings in Natera by 3.0% in the 2nd quarter. Zweig DiMenna Associates LLC now owns 124,100 shares of the medical research company's stock worth $20,965,000 after buying an additional 3,610 shares during the last quarter. Earned Wealth Advisors LLC boosted its holdings in Natera by 7.3% in the 2nd quarter. Earned Wealth Advisors LLC now owns 1,864 shares of the medical research company's stock worth $315,000 after buying an additional 127 shares during the last quarter. Finally, Simon Quick Advisors LLC boosted its holdings in shares of Natera by 27.7% during the 2nd quarter. Simon Quick Advisors LLC now owns 2,045 shares of the medical research company's stock worth $345,000 after purchasing an additional 444 shares during the last quarter. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.